Trial
NCT04260009
Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Takeda
Collaborators
—
Condition
Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma
Intervention
Brigatinib
Why stopped
Business reason unrelated to product safety
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-03-05